FDA Approves Biohaven's Nurtec ODT (rimegepant) for Preventative Treatment of Migraine

Article Link: FDA Approves Biohaven’s Nurtec ODT (rimegepant) for Preventative Treatment of Migraine

Nurtec ODT 75 mg is the first oral CGRP antagonist approved to prevent migraine
Nurtec ODT 75 mg is now the only migraine medication approved to both treat acute migraine attacks and help prevent future migraine attacks
In a pivotal Phase 3…

Source: FDA New Drug Approvals